
Lantern Pharma Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer
Lantern Pharma has completed targeted patient enrollment in Japan for its Phase 2 HARMONIC trial evaluating LP-300 in never-smoker non-small cell lung cancer patients, advancing treatment options for this underserved population with significant unmet medical need.
Read full story
























